<DOC>
	<DOCNO>NCT01119846</DOCNO>
	<brief_summary>The purpose study see GSK1292263 safe well-tolerated administer type 2 diabetic , get preliminary information whether may effective treatment type 2 diabetes .</brief_summary>
	<brief_title>A Study Type 2 Diabetics Single Multiple Doses Orally Administered GSK1292263 Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics</brief_title>
	<detailed_description>Data study use assess potential GSK1292263 treatment T2DM , aid design dose selection future study longer duration T2DM subject evaluate GSK1292263 alone combination anti-diabetic drug .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female subject , 18 60 year age , inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential , define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . FSH estradiol level check Screening postmenopausal woman . Simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40pg/ml ( &lt; 140pmol/L ) confirmatory . Except note elsewhere , subject significant know medical condition T2DM , determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test ECGs . A subject clinical abnormality laboratory parameter meet exclusion criterion outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . BMI ( body mass index ) within range 2235 kg/m2 , inclusive . Part A T2DM diagnosed American Diabetes Association criteria least 3 month prior Screening : Currently control diet exercise . Fasting plasma glucose ( FPG ) level &lt; = 250mg/dL Screening visit FPG level &lt; = 250mg/dL Day 1 HbA1c 6.5 11 % , inclusive , Screening visit For Parts B C , T2DM diagnose American Diabetes Association criteria least 3 month prior Screening : T2DM currently control diet exercise , , medication , subject must treat T2DM use one follow regimen : Metformin monotherapy Sulfonylurea monotherapy Metformin sulfonylurea combination , component administer dos half maximum dose less DPPIV inhibitor , either monotherapy combination agent ( ) list half maximal dose less Exenatide , either monotherapy combination agent ( ) list half maximal dose less For subject screen Parts B C , dose antidiabetic medication must stable least 3 month prior Screening , subject must willing wash antidiabetic medication Day 7 postlastdose Period 2 ( Part B ) Day 7 Day 15 ( Part C ) . Fasting plasma glucose ( FPG ) level &lt; = 220mg/dL Screening visit FPG level &lt; = 250mg/dL Day 1 HbA1c 7 11 % , inclusive , Screening visit Capable give write informed consent , include compliance requirement restriction list consent form . Has follow laboratory abnormality : Positive prestudy Hepatitis B surface antigen positive Hepatitis C , result within 3 month screen . Positive test HIV antibody . History uncorrected thyroid dysfunction abnormal thyroid function test assess TSH Screening . ( NOTE : subject hypothyroidism stable dose thyroid replacement therapy least 3 month prior Screening screen thyroid stimulate hormone ( TSH ) within normal range may participate . ) ALT and/or AST &gt; 2 time upper limit normal screening . Fasting triglyceride &gt; 450mg/dL screening . Total Bilirubin &gt; 1.5 time upper limit normal screening . For female haemoglobin &lt; 11.5 g/dL , male hemoglobin &lt; 12.5 g/dL . Hemoglobin &lt; 11g/dL ( A female subject haemoglobin 10g/dL 11.5 g/dL , male subject haemoglobin 10g/dL 12.5 g/dLmay enrol Investigator GSK Medical Monitor agree find unlikely introduce additional risk subject interfere study procedure ) . A positive prestudy drug/urine screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A prestudy urine cotinine screen indicate use tobacco/ nicotine containing product . If female pregnant positive pregnancy test Significant renal disease manifest one following : Creatinine clearance &lt; 60mL/min . ( estimate serum creatinine ( SCr ) demographic data use MDRD calculation ) : To calculate estimate GFR ( mL/min/1.73m2 ) manually : =186 x ( SCr mg/dL ) 1.154 x ( age ) 0.203 x ( 0.742 female ) x ( 1.210 AfricanAmerican ) =exp ( 5.2281.154 x ln ( SCr ) 0.203x ln ( age ) ( 0.299 female ) + ( 0.192 African American ) ) ( A link validate MDRD calculator internet provide SRM . ) Urine protein/creatinine ( mg protein/mg creatinine ) ratio &gt; 2.5 ; urine albumin concentration &gt; 300mg/g creatinine ) . Known loss kidney either surgical ablation , injury , disease . Significant ECG abnormality , define follow : Heart Rate &lt; 50 &gt; 100bpm PR Interval &lt; 120 &gt; 220ms QRS duration &lt; 70 &gt; 120ms QTC Interval ( Bazett ) * &gt; 450ms Or , clinically significant rhythm abnormality identify 24hour Screening Holter assessment . Subjects Left Bundle Branch Block exclude study . Subjects partial Right Bundle Branch Block may consider inclusion follow consultation GSK Medical Monitor . Subjects WPW syndrome exclude study . *Note ECG abnormality identify , ECG repeat two time ( 5 minute ECG reading ) average 3 value use determine eligibility . Systolic pressure &gt; 150mmHg &lt; 80mmHg diastolic blood pressure &gt; 95mmHg &lt; 60mmHg screening . Blood pressure assessment may repeat need , allow adequate time subject rest . Previous use insulin treatment within 3 month Screening , &gt; 2 week use acute illness last 12 month prior Screening , use 1 year associate gestational diabetes mellitus . Has history follow condition : Clinically significant symptom gastroparesis Cholelithiasis obstructive inflammatory gallbladder disease within 3 month prior Screening Gastrointestinal disease could affect fat bile acid absorption , include inflammatory bowel disease , chronic diarrhea , Crohn 's malabsorption syndrome within past year Gastrointestinal surgery Chronic acute pancreatitis History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360mL ) beer , 5 ounce ( 150mL ) wine 1.5 ounce ( 45mL ) 80 proof distil spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Has participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . Is take prohibited medication . See Section 9.3 detailed list prohibit medication . Note also : The use antidiabetic agent list Inclusion # 7 reason exclusion subject allow wash unapproved antidiabetic medication order qualify participation study . Subjects must wash follow medication 7day period prior first dose , must remain medication discharge postlastdose Period 2 ( Part B ) Day 15 ( Part C ) : antidiabetic medication specify Inclusion # 7 , statin agent , fat absorption block agent , bile acid sequestrants . Fibrates must wash 14day period prior first dose . Vitamins , herbal dietary supplement ( include St John 's Wort ) prohibit within 7 day 5 halflives ( whichever longer ) prior first dose study medication discharge . Unwilling abstain Caffeineor xanthinecontaining product 24 hour prior dose postlastdose Period 5 ( Part A ) , postlastdose Period 2 ( Part B ) Day 7 Day 15 ( Part C ) . Use illicit drug nicotinecontaining product Alcohol 24 hour prior dose postlastdose Period 5 ( Part A ) , postlastdose Period 2 ( Part B ) Day 7 Day 15 ( Part C ) . Consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose study medication collection final pharmacokinetic blood sample . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . This include sensitivity heparin heparininduced thrombocytopenia , heparin use maintain catheter patency . Where participation study would result donation blood excess approximately 500mL within 56 day period . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Glucose</keyword>
</DOC>